These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7279993)

  • 1. [Pharmaceutical and biopharmaceutical evaluation of acetylaminonitropropoxybenzene (Falimint). 1. Studies on the purity of active substances].
    Gerlach K; Fürst W
    Pharmazie; 1981 Jun; 36(6):442. PubMed ID: 7279993
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmaceutical and biopharmaceutical evaluation of acetylaminonitropropoxybenzene (Falimint). 2. Purity studies with a multi-stage phase solubility analysis and evaluation].
    Gerlach K; Fürst W
    Pharmazie; 1981 Jun; 36(6):442-3. PubMed ID: 7279994
    [No Abstract]   [Full Text] [Related]  

  • 3. [The pharmaceutical and biopharmaceutical evaluation of acetylaminonitropropoxybenzene (Falimint). Biotransformation of the agent in various animal species].
    Fürst W; Becher M
    Pharmazie; 1990 Jun; 45(6):440-1. PubMed ID: 2402533
    [No Abstract]   [Full Text] [Related]  

  • 4. [The pharmaceutical and biopharmaceutical assessment of acetylaminonitropropoxybenzene (Falimint). 6. Quantitative composition of metabolites].
    Gerlach K; Metzner J; Fürst W
    Pharmazie; 1985 Aug; 40(8):564-5. PubMed ID: 3878528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmaceutical and biopharmaceutical evaluation of acetylaminonitropropoxybenzolum (Falimint). 3: Polarographic analysis and determination of active agents].
    Gerlach K; Voigtländer R; Fürst W
    Pharmazie; 1983 Aug; 38(8):527-30. PubMed ID: 6634923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmaceutical and biopharmaceutical evaluation of acetylaminonitropropoxybenzolum (Falimint). 8. Biotransformation of the active agents].
    Becher M; Fürst W
    Pharmazie; 1989 Jan; 44(1):56-7. PubMed ID: 2786218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmaceutical and biopharmaceutical evaluation of acetylaminonitropopoxybenzolum (Falimint). 10. Biotransformation of the active substance in chick embryo and in in vitro systems].
    Fürst W; Becher M
    Pharmazie; 1990 Jul; 45(7):534-5. PubMed ID: 2236198
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pharmaceutical and biopharmaceutical assessment of acetylaminopropoxybenzene (Falimint). 5. Characterization of metabolites of Falimint with square wave- and oscillopolarography].
    Gerlach K; Fürst W
    Pharmazie; 1984 May; 39(5):354-5. PubMed ID: 6332324
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pharmaceutic and biopharmaceutic evaluation of acetylaminonitropropoxybenzene (Falimint). A Biotransformation of the active agent].
    Gerlach K; Büge A; Peinhardt G; Fürst W
    Pharmazie; 1984 Jan; 39(1):42-5. PubMed ID: 6718467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmaceutical and biopharmaceutical evaluation of acetylaminonitropropoxybenzolum (Falimint). 11. Plasma levels and urinary elimination in single and multiple administration].
    Metzner J; Becher M; Fürst W; Gerlach K
    Pharmazie; 1990 Sep; 45(9):693. PubMed ID: 2284320
    [No Abstract]   [Full Text] [Related]  

  • 11. [On the determination of chlorinated substances in phenacetin and in intermediate products during phenacetin synthesis].
    Dimofte L; Arizan S; Simionovici R; Sterescu M; Popa M; Rizescu I
    Pharmazie; 1969 Feb; 24(2):108-10. PubMed ID: 5771403
    [No Abstract]   [Full Text] [Related]  

  • 12. [Contamination of phenacetin with chloro-organic compounds].
    Sokolowska I; Borkowska Z
    Acta Pol Pharm; 1973; 30(6):575-9. PubMed ID: 4775908
    [No Abstract]   [Full Text] [Related]  

  • 13. Aspects of the purity control of drugs.
    Hoeke M
    Pharm Weekbl; 1971 Oct; 106(38):709-19. PubMed ID: 5159657
    [No Abstract]   [Full Text] [Related]  

  • 14. A limit test for 4-chloroacetanilide in phenacetin and its preparations.
    Analyst; 1967 May; 92(94):290-2. PubMed ID: 6046819
    [No Abstract]   [Full Text] [Related]  

  • 15. Gas chromatographic analysis of phenacetin and probable contaminants--acetanilid, p-chloroacetanilid, and p-phenetidin.
    Koshy KT; Wickersham HC; Duvall RN
    J Pharm Sci; 1965 Oct; 54(10):1547-9. PubMed ID: 5883240
    [No Abstract]   [Full Text] [Related]  

  • 16. [Determination of impurities in phenacetin, especially of p-chloroacetanilide by thin layer chromatography].
    Thoma F
    Arzneimittelforschung; 1966 Jun; 16(6):771-3. PubMed ID: 6014591
    [No Abstract]   [Full Text] [Related]  

  • 17. [Method of phase solubility and its use in phamaceutical analysis].
    Pakholkov GV; Arzamastsev AP
    Farmatsiia; 1975; 24(2):82-5. PubMed ID: 1100440
    [No Abstract]   [Full Text] [Related]  

  • 18. Dielectric solubility profiles of acetanilide and several derivatives in ioxane--water mixtures.
    Paruta AN; Sciarrone BJ; Lordi NG
    J Pharm Sci; 1965 Sep; 54(9):1325-33. PubMed ID: 5881230
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pharmaceutical aspects of drug side effects].
    Speiser P
    Ther Umsch; 1993 Jan; 50(1):37-41. PubMed ID: 8378865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Determination of residual solvents in ranolazine by headspace gas chromatography].
    Ye YL; Yang XM
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jan; 28(1):134-5. PubMed ID: 18227046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.